Avenue Therapeutics (ATXI)
(Delayed Data from NSDQ)
$4.77 USD
+0.01 (0.21%)
Updated May 2, 2024 03:59 PM ET
After-Market: $4.75 -0.02 (-0.42%) 4:56 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ATXI 4.77 +0.01(0.21%)
Will ATXI be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for ATXI based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for ATXI
Why Clever Leaves Holdings Shares Are Trading Lower By Around 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
FLGC, BTOG and CAUD among mid-day movers
ImmunityBio, Aquestive Therapeutics, Clever Leaves Holdings among healthcare movers
Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds
ALT, CYCC and DB among pre-market losers